

Multiple Myeloma

**Dose-Escalation Study of BFCR4350A in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)**

**Trial Status**  
Recruiting

**Trial Runs In**  
4 Countries

**Trial Identifier**  
NCT03275103 GO39775

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

This is a phase I, multicenter, open-label, dose-escalation study of cevostamab administered as a single agent by IV infusion to participants with relapsed or refractory multiple myeloma (R/R MM).

**Genentech, Inc.**  
Sponsor

**Phase 1**  
Phase

---

**NCT03275103 GO39775**  
Trial Identifiers

---

***Eligibility Criteria:***

**Gender**  
All

**Age**  
>= 18 Years

**Healthy Volunteers**  
No

---